¹Bejing Anding Hospital, Capital Medical University, Good Clinical Practice Center, Beijing, China

Background: Depression is a leading cause of mental health-related disability globally. The development of novel antidepressants is hampered by significant and increasing placebo effects in clinical trials, which obscure true drug efficacy and pose a major challenge for demonstrating treatment effectiveness.

Aims & Objectives: To propose a practical, multi-dimensional framework for detecting and reducing the placebo effect in clinical trials for major depressive disorder (MDD), aiming to enhance the accuracy of efficacy evaluation for new antidepressants.​

Method: The framework integrates strategies across three core trial phases: Design, Execution, and Data Analysis. Design-phase strategies include stringent baseline severity criteria, a placebo run-in period, and innovative designs such as the sequential parallel comparison design (SPCD). Execution-phase measures focus on standardizing informed consent with neutral language, employing independent evaluators, maintaining consistent rater-subject pairings, and utilizing centralized ratings to minimize expectancy and rater bias. Analysis-phase approaches involve statistical methods like joint causal modeling, non-linear mixed models for repeated measures (NLMMRM) with site weighting, and latent variable/mixture models to account for and adjust placebo response heterogeneity.

Results: The framework provides a structured approach to identify high placebo responders early, control for expectancy and observational biases during trial conduct, and statistically isolate the drug effect from placebo response. It synthesizes evidence-based methodologies to strengthen trial validity and sensitivity.

Discussion & Conclusions: This quick-reference framework offers trialists, sponsors, and regulators a consolidated strategy to mitigate placebo effects in antidepressant trials. By optimizing design, ensuring rigorous execution, and applying advanced analytics, the framework can improve the detection of true treatment signals, accelerate the development of effective antidepressants, and ultimately expand treatment options for patients with MDD. Future integration with biomarkers and digital phenotyping holds promise for further refinement.